(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback